Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system

Walmor C De Mello1

  • 1Department of Pharmacology, Medical Sciences Campus, University Puerto Rico, P.O. Box 365067, San Juan, PR 00936-5067, USA. wmello@rcm.upr.edu

Insights

Heart failure involves complex cellular changes, including impaired cell coupling and fibrosis. This review explores how the renin-angiotensin-aldosterone system contributes to these issues and how ACE inhibitors improve synchronization.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pathophysiology

Background:

  • Heart failure is characterized by declining heart contractility and involves inflammatory cytokines, endothelin, angiotensin II, and aldosterone.
  • These alterations lead to cellular and molecular changes, impairing cell coupling, impulse propagation, and causing morphologic changes.

Purpose of the Study:

  • To discuss the role of cellular sequestration, impaired cell coupling, and interstitial fibrosis in heart failure development.
  • To describe the involvement of plasma and cardiac renin-angiotensin-aldosterone systems in cellular sequestration.
  • To explore the potential role of an intracellular renin-angiotensin system in intercellular signaling.

Main Methods:

  • Review of existing literature on heart failure pathophysiology.
  • Analysis of the renin-angiotensin-aldosterone system's role in cellular processes.
  • Discussion of the mechanisms of action for angiotensin-converting enzyme inhibitors.

Main Results:

  • Impaired cell coupling and interstitial fibrosis may contribute to cellular sequestration in heart failure.
  • Both plasma and cardiac renin-angiotensin-aldosterone systems are implicated in cellular sequestration.
  • An intracellular renin-angiotensin system might play a role in intercellular signaling.

Conclusions:

  • Angiotensin-converting enzyme inhibitors demonstrate beneficial effects by improving cellular synchronization.
  • Improvements include enhanced cell coupling, cell membrane hyperpolarization, and favorable morphologic remodeling.
  • These effects contribute to decreased interstitial fibrosis and ventricular hypertrophy, ameliorating heart failure progression.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...